期刊
CELLS
卷 11, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/cells11010166
关键词
antibiotic resistance; bacterial infection; Streptococcus; toxin; liposome; nanotrap; immune cells; antivirulence
类别
资金
- Novartis Foundation [16B100]
- Fund for Nanoscience Solutions (University of Bern)
The increasing antibiotic resistance has led to the development of non-antibiotic treatments, such as antivirulence therapy. In this study, a liposomal nanotrap formulation was developed to protect immune cells from the cytolytic effects of streptococcal exotoxins, suggesting the potential of liposomal antivirulence therapy for more effective treatment of bacterial infections.
The increasing antibiotic resistance of bacterial pathogens fosters the development of alternative, non-antibiotic treatments. Antivirulence therapy, which is neither bacteriostatic nor bactericidal, acts by depriving bacterial pathogens of their virulence factors. To establish a successful infection, many bacterial pathogens secrete exotoxins/cytolysins that perforate the host cell plasma membrane. Recently developed liposomal nanotraps, mimicking the outer layer of the targeted cell membranes, serve as decoys for exotoxins, thus diverting them from attacking host cells. In this study, we develop a liposomal nanotrap formulation that is capable of protecting immortalized immune cells from the whole palette of cytolysins secreted by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis-important human pathogens that can cause life-threatening bacteremia. We show that the mixture of cholesterol-containing liposomes with liposomes composed exclusively of phospholipids is protective against the combined action of all streptococcal exotoxins. Our findings pave the way for further development of liposomal antivirulence therapy in order to provide more efficient treatment of bacterial infections, including those caused by antibiotic resistant pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据